Photo: Contributed Those with major depressive disorder are invited to take part in an Okanagan Clinical Trials study. Okanagan Clinical Trials is inviting individuals living with major depressive disorder to participate in an ongoing medication research …

… ;postpartum-depression-drug-market/2462 Postpartum Depression drug Market Overview: Global Postpartum Depression drug market … /postpartum-depression-drug-market/2462 Analyst Perspective: Postpartum Depression Drugs Market is …

… is no potential for improvement. Depression, drugs, violence, neglect, and repeat – the …

… as allusions to self-harm, depression, drug use and violence.  In court …

The share price of Alto Neuroscience more than doubled at one point Monday, after the psychiatry drug specialist announced plans to hasten the development of a potential depression medicine. This medicine, code-named ALTO-207, combines a drug already used …

Autism rates in the US have increased approximately 380 percent since monitoring began in 2000, with recent data showing one in 31 children are affected.  Health experts around the world have been trying to find a cause for the rapid rise, and last month …

When Katharine Unetic was a little girl, growing up in San Diego, she spent a lot of time crying. Especially when she was in school. “There was this one art project in the first grade, that I still remember, when I broke down crying. We had to tear pieces …

Atai Life Sciences ATAI and Beckley Psytech Limited, a private clinical-stage biopharmaceutical company, released data from a proof-of-concept study investigating a two-dose induction regimen of BPL-003 (intranasal mebufotenin benzoate) in patients with …

The medicine becomes the first EU-approved oral treatment for adults who have postpartum depression (PPD). The European Commission (EC) has authorised Biogen’s Zurzuvae (zuranolone) for women with post-partum depression (PPD), making it the first oral …